| Literature DB >> 26859457 |
Mélodie Grandin1, Markus Meier2, Jean Guy Delcros1, Denise Nikodemus3, Raphael Reuten4, Trushar R Patel5, David Goldschneider6, George Orriss2, Natalie Krahn2, Amina Boussouar1, Riad Abes7, Yann Dean7, David Neves7, Agnes Bernet6, Stephane Depil7, Fiona Schneiders4, Kate Poole8, Robert Dante1, Manuel Koch3, Patrick Mehlen9, Jörg Stetefeld10.
Abstract
Netrin-1 has been shown to be up-regulated in a fraction of human cancers as a mechanism to allow these tumors to escape the pro-apoptotic activity of some of its main dependence receptors, the UNC5 homologs (UNC5H). Here we identify the V-2 domain of netrin-1 to be important for its interaction with the Ig1/Ig2 domains of UNC5H2. We generate a humanized anti-netrin-1 antibody that disrupts the interaction between netrin-1 and UNC5H2 and triggers death of netrin-1-expressing tumor cells in vitro. We also present evidence that combining the anti-netrin-1 antibody with epidrugs such as decitabine could be effective in treating tumors showing no or modest netrin-1 expression. These results support that this antibody is a promising drug candidate.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26859457 DOI: 10.1016/j.ccell.2016.01.001
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743